Abstract | BACKGROUND: OBJECTIVE: This review describes the mechanism of action, pharmacokinetics, adverse-effect profile, drug-interaction potential, and dosing of olmesartan medoxomil. The results of relevant clinical efficacy and safety trials are also discussed. METHODS: This review is based on data from published clinical efficacy and safety trials and abstracts of conference presentations. To identify appropriate English-language publications for review, MEDLINE (1966-October 2002) and EMBASE (1990-2002) were searched using the terms olmesartan medoxomil, CS-866, angiotensin II-receptor blocker, and hypertension. RESULTS: CONCLUSIONS: Based on the available literature, olmesartan medoxomil is an effective ARB for the treatment of hypertension, with a favorable adverse-effect and drug-interaction profile.
|
Authors | Julie A Brousil, John M Burke |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 25
Issue 4
Pg. 1041-55
(Apr 2003)
ISSN: 0149-2918 [Print] United States |
PMID | 12809956
(Publication Type: Journal Article, Review)
|
Chemical References |
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
- Imidazoles
- Tetrazoles
- Angiotensin II
- Olmesartan Medoxomil
|
Topics |
- Angiotensin II
(metabolism)
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
(adverse effects, pharmacology, therapeutic use)
- Clinical Trials as Topic
- Drug Interactions
- Humans
- Hypertension
(drug therapy)
- Imidazoles
(adverse effects, pharmacology, therapeutic use)
- Olmesartan Medoxomil
- Tetrazoles
(adverse effects, pharmacology, therapeutic use)
|